Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity.

Jane A Leopold, Aamir Dam, Bradley A Maron, Anne W Scribner, Ronglih Liao, Diane E Handy, Robert C Stanton, Bertram Pitt, Joseph Loscalzo
Author Information
  1. Jane A Leopold: Whitaker Cardiovascular Institute, 700 Albany Street, Boston University School of Medicine, Boston, Massachusetts 02118, USA. jleopold@partners.org

Abstract

Hyperaldosteronism is associated with impaired vascular reactivity; however, the mechanisms by which aldosterone promotes endothelial dysfunction remain unknown. Glucose-6-phosphate dehydrogenase (G6PD) modulates vascular function by limiting oxidant stress to preserve bioavailable nitric oxide (NO(*)). Here we show that aldosterone (10(-9)-;10(-7) mol/l) decreased endothelial G6PD expression and activity in vitro, resulting in increased oxidant stress and decreased NO(*) levels-similar to what is observed in G6PD-deficient endothelial cells. Aldosterone decreased G6PD expression by increasing expression of the cyclic AMP-response element modulator (CREM) to inhibit cyclic AMP-response element binding protein (CREB)-mediated G6PD transcription. In vivo, infusion of aldosterone decreased vascular G6PD expression and impaired vascular reactivity. These effects were abrogated by spironolactone or vascular gene transfer of G6pd. These findings demonstrate that aldosterone induces a G6PD-deficient phenotype to impair endothelial function; aldosterone antagonism or gene transfer of G6pd improves vascular reactivity by restoring G6PD activity.

References

  1. J Lab Clin Med. 2003 Aug;142(2):71-82 [PMID: 12960953]
  2. Circulation. 2004 Apr 27;109(16):1933-7 [PMID: 15078792]
  3. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):239-41 [PMID: 15134823]
  4. Biochemistry. 2004 Jun 8;43(22):7197-206 [PMID: 15170357]
  5. Am J Cardiol. 2004 Jun 15;93(12):1564-6 [PMID: 15194040]
  6. Circulation. 2004 Jun 15;109(23):2857-61 [PMID: 15173035]
  7. Heart. 2004 Jul;90(7):765-70 [PMID: 15201246]
  8. Circulation. 2004 Sep 28;110(13):1819-25 [PMID: 15364804]
  9. Can J Physiol Pharmacol. 1969 Feb;47(2):193-7 [PMID: 4389001]
  10. Biochim Biophys Acta. 1969 Sep 2;184(3):486-94 [PMID: 4390358]
  11. J Biol Chem. 1996 Mar 29;271(13):7336-42 [PMID: 8631754]
  12. Arterioscler Thromb Vasc Biol. 1997 Aug;17(8):1599-604 [PMID: 9301641]
  13. Am J Hypertens. 1997 Dec;10(12 Pt 1):1326-34 [PMID: 9443767]
  14. J Biol Chem. 1998 Feb 27;273(9):4883-91 [PMID: 9478930]
  15. Eur Heart J. 1998 Sep;19(9):1371-6 [PMID: 9792263]
  16. Mol Endocrinol. 1999 Jan;13(1):57-65 [PMID: 9892012]
  17. Diabetologia. 2004 Oct;47(10):1687-94 [PMID: 15365622]
  18. Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4459-64 [PMID: 15753290]
  19. J Neurosci. 2005 Apr 20;25(16):4073-81 [PMID: 15843609]
  20. Circulation. 2005 Jul 12;112(2):257-63 [PMID: 15998684]
  21. Diabetologia. 2005 Sep;48(9):1933-40 [PMID: 16034613]
  22. Am J Physiol Renal Physiol. 2005 Nov;289(5):F1040-7 [PMID: 15956780]
  23. Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14771-6 [PMID: 16186489]
  24. Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):16967-72 [PMID: 16284254]
  25. Br J Pharmacol. 2005 Dec;146(8):1110-8 [PMID: 16231005]
  26. Hypertension. 2006 Jul;48(1):165-71 [PMID: 16754797]
  27. Circulation. 2000 Feb 15;101(6):594-7 [PMID: 10673249]
  28. Methods Enzymol. 2003;370:396-415 [PMID: 14712663]
  29. J Neurochem. 2003 Dec;87(6):1313-20 [PMID: 14713288]
  30. J Biol Chem. 2000 Apr 14;275(15):11278-83 [PMID: 10753938]
  31. J Clin Invest. 2000 Aug;106(4):483-91 [PMID: 10953023]
  32. Anal Biochem. 2000 Oct 1;285(1):163-7 [PMID: 10998277]
  33. Am J Physiol Heart Circ Physiol. 2000 Nov;279(5):H2477-85 [PMID: 11045985]
  34. J Biol Chem. 2000 Dec 22;275(51):40042-7 [PMID: 11007790]
  35. FASEB J. 2001 Aug;15(10):1771-3 [PMID: 11481225]
  36. N Engl J Med. 2001 Dec 6;345(23):1689-97 [PMID: 11759649]
  37. Biochem J. 2002 Jan 15;361(Pt 2):267-76 [PMID: 11772398]
  38. Mol Endocrinol. 2002 Jan;16(1):184-99 [PMID: 11773448]
  39. Adv Physiol Educ. 2002 Dec;26(1-4):8-20 [PMID: 11850323]
  40. J Am Soc Nephrol. 2002 May;13(5):1190-8 [PMID: 11961006]
  41. Am J Pathol. 2002 Nov;161(5):1773-81 [PMID: 12414524]
  42. J Am Coll Cardiol. 2002 Nov 6;40(9):1596-601 [PMID: 12427411]
  43. Biochemistry. 2002 Dec 17;41(50):14726-33 [PMID: 12475221]
  44. Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):411-7 [PMID: 12615686]
  45. Cardiovasc Res. 2003 Jun 1;58(3):655-62 [PMID: 12798439]
  46. Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1352-7 [PMID: 12829522]
  47. J Biol Chem. 2003 Aug 22;278(34):32100-6 [PMID: 12777375]

Grants

  1. HL58976/NHLBI NIH HHS
  2. K08 HL004399-01/NHLBI NIH HHS
  3. HL04399/NHLBI NIH HHS
  4. HV28178/NHLBI NIH HHS
  5. R01 HL073756-01/NHLBI NIH HHS
  6. P50 HL055993/NHLBI NIH HHS
  7. R01 HL073756/NHLBI NIH HHS
  8. R37 HL061795/NHLBI NIH HHS
  9. HL081110/NHLBI NIH HHS
  10. HL067297/NHLBI NIH HHS
  11. HL071775/NHLBI NIH HHS
  12. R01 HL058976-08/NHLBI NIH HHS
  13. R01 HL071775/NHLBI NIH HHS
  14. N01 HV028178/NHLBI NIH HHS
  15. U01 HL108630/NHLBI NIH HHS
  16. P50 HL055993-10/NHLBI NIH HHS
  17. R01 DK054380/NIDDK NIH HHS
  18. R01 HL071775-01A1/NHLBI NIH HHS
  19. R01 DK054380-04S1/NIDDK NIH HHS
  20. R01 HL067297/NHLBI NIH HHS
  21. P01 HL81587/NHLBI NIH HHS
  22. DK053480-05/NIDDK NIH HHS
  23. K02 HL081110/NHLBI NIH HHS
  24. N01HV28178/NHLBI NIH HHS
  25. HL61828/NHLBI NIH HHS
  26. K02 HL081110-01/NHLBI NIH HHS
  27. K08 HL004399/NHLBI NIH HHS
  28. R01 HL067297-01A2/NHLBI NIH HHS
  29. R01 HL058976/NHLBI NIH HHS
  30. HL073756/NHLBI NIH HHS

MeSH Term

Aldosterone
Analysis of Variance
Blotting, Northern
Cells, Cultured
Chromatin Immunoprecipitation
Cyclic AMP
Cyclic AMP Response Element Modulator
Cyclic AMP-Dependent Protein Kinases
DNA Primers
Electrophoretic Mobility Shift Assay
Endothelium, Vascular
Gene Expression Regulation, Enzymologic
Gene Transfer Techniques
Glucosephosphate Dehydrogenase
Humans
Immunoblotting
Mineralocorticoid Receptor Antagonists
Nitric Oxide
Spironolactone

Chemicals

CREM protein, human
DNA Primers
Mineralocorticoid Receptor Antagonists
Cyclic AMP Response Element Modulator
Spironolactone
Nitric Oxide
Aldosterone
Cyclic AMP
Glucosephosphate Dehydrogenase
Cyclic AMP-Dependent Protein Kinases

Word Cloud

Created with Highcharts 10.0.0vascularG6PDaldosteronereactivityendothelialdecreasedexpressionactivityimpaireddehydrogenasefunctionoxidantstressNO*10G6PD-deficientAldosteronecyclicAMP-responseelementgenetransferG6pdHyperaldosteronismassociatedhowevermechanismspromotesdysfunctionremainunknownGlucose-6-phosphatemodulateslimitingpreservebioavailablenitricoxideshow-9--7mol/lvitroresultingincreasedlevels-similarobservedcellsincreasingmodulatorCREMinhibitbindingproteinCREB-mediatedtranscriptionvivoinfusioneffectsabrogatedspironolactonefindingsdemonstrateinducesphenotypeimpairantagonismimprovesrestoringimpairsdecreasingglucose-6-phosphate

Similar Articles

Cited By